The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens

Biological Psychiatry

Volumn 72, Issue 10, 2012, Pages 823-831

  Steensland, Pia ^a   Fredriksson, Ida ^a   Holst, Sarah ^a   Feltmann, Kristin ^a   Franck, Johan ^a   Schilström, Björn ^b   Carlsson, Arvid ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alcohol; dependence; dopamine stabilizer; drug development; microdialysis; partial agonist

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; ALCOHOL; EPININE;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ALCOHOL DRINKING; ANIMALS; BEHAVIORAL SYMPTOMS; CUES; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DISCOVERY; ETHANOL; MALE; MICRODIALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; PIPERIDINES; RATS; RECURRENCE; REWARD; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84867743493     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.06.018     Document Type: Article

References (58)

1. R.F. Anton, S.S. O'Malley, D.A. Ciraulo, R.A. Cisler, D. Couper, D.M. Donovan Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial JAMA 295 2006 2003 2017
2. D.W. Oslin, W.H. Berrettini, C.P. O'Brien Targeting treatments for alcohol dependence: The pharmacogenetics of naltrexone Addict Biol 11 2006 397 403
3. A. Heinz, M. Schafer, J.D. Higley, J.H. Krystal, D. Goldman Neurobiological correlates of the disposition and maintenance of alcoholism Pharmacopsychiatry 36 suppl 3 2003 S255 S258
4. V. Vengeliene, A. Bilbao, A. Molander, R. Spanagel Neuropharmacology of alcohol addiction Br J Pharmacol 154 2008 299 315
5. R. Swift Medications acting on the dopaminergic system in the treatment of alcoholic patients Curr Pharm Des 16 2010 2136 2140
6. G.A. Wiesbeck, H.G. Weijers, O.M. Lesch, T. Glaser, P.J. Toennes, J. Boening Flupenthixol decanoate and relapse prevention in alcoholics: Results from a placebo-controlled study Alcohol Alcohol 36 2001 329 334
7. N.D. Volkow, G.J. Wang, F. Telang, J.S. Fowler, J. Logan, M. Jayne Profound decreases in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement J Neurosci 27 2007 12700 12706
8. N.D. Volkow, G.J. Wang, L. Maynard, J.S. Fowler, B. Jayne, F. Telang Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: A preliminary study Psychiatry Res 116 2002 163 172
9. J. Guardia, A.M. Catafau, F. Batlle, J.C. Martín, L. Segura, B. Gonzalvo Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients Am J Psychiatry 157 2000 127 129
10. F. Weiss, L.H. Parsons, G. Schulteis, P. Hyytiä, M.T. Lorang, F.E. Bloom, G.F. Koob Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats J Neurosci 16 1996 3474 3485
11. A. Carlsson, M.L. Carlsson A dopaminergic deficit hypothesis of schizophrenia: The path to discovery Dialogues Clin Neurosci 8 2006 137 142
12. K. Ingman, J. Kupila, P. Hyytia, E.R. Korpi Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking Alcohol Alcohol 41 2006 391 398
13. G. Martinotti, M. Di Nicola, M. Di Giannantonio, L. Janiri Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. naltrexone J Psychopharmacol 23 2009 123 129
14. G. Martinotti, M. Di Nicola, L. Janiri Efficacy and safety of aripiprazole in alcohol dependence Am J Drug Alcohol Abuse 33 2007 393 401
15. K. Voronin, P. Randall, H. Myrick, R. Anton Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm - possible influence of self-control Alcohol Clin Exp Res 32 2008 1954 1961
16. H. Myrick, X. Li, P.K. Randall, S. Henderson, K. Voronin, R.F. Anton The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics J Clin Psychopharmacol 30 2010 365 372
17. C. Sonesson, C.H. Lin, L. Hansson, N. Waters, K. Svensson, A. Carlsson Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships J Med Chem 37 1994 2735 2753
18. M.L. Carlsson, A. Carlsson, M. Nilsson Schizophrenia: From dopamine to glutamate and back Curr Med Chem 11 2004 267 277
19. A. Ekesbo, R. Torstenson, P. Hartvig, A. Carlsson, C. Sonesson, N. Waters Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains Neuropharmacology 38 1999 331 338
20. S. Natesan, K.A. Svensson, G.E. Reckless, J.N. Nobrega, K.B. Barlow, A.M. Johansson, S. Kapur The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl) -1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl- piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat J Pharmacol Exp Ther 318 2006 810 818
21. T. Dyhring, EO Nielsen, C. Sonesson, F. Pettersson, J. Karlsson, P. Svensson The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties Eur J Pharmacol 628 2010 19 26
22. E. Kara, H. Lin, K. Svensson, A.M. Johansson, P.G. Strange Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor Br J Pharmacol 161 2010 1343 1350
23. P. Seeman, H.C. Guan Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis Eur J Pharmacol 557 2007 151 153
24. J.P. Rung, E. Rung, L. Helgeson, A.M. Johansson, K. Svensson, A. Carlsson, M.L. Carlsson Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization J Neural Transm 115 2008 899 908
25. E.S. Burstein, M.L. Carlsson, M. Owens, J.N. Ma, H.H. Schiffer, A. Carlsson, U. Hacksell II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors J Neural Transm 118 2011 1523 1533
26. M.L. Carlsson, E.S. Burstein, A. Kloberg, S. Hansson, A. Schedwin, M. Nilsson I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors J Neural Transm 118 2011 1511 1522
27. J.G. de Yebenes, B. Landwehrmeyer, F. Squitieri, R. Reilmann, A. Rosser, R.A. Barker Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial Lancet Neurol 10 2011 1049 1057
28. O. Gefvert, L.H. Lindström, O. Dahlbäck, C. Sonesson, N. Waters, A. Carlsson (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled pilot study. Scandinavian Society for Psychopharmacology 41st annual meeting, Copenhagen, Denmark Nord J Psychiatry 54 2000 93 94
29. T. Lundberg, J. Tedroff, N. Waters, C. Sonesson, A. Carlsson, P. Hagström et al. Safety of early clinical experience with (-)-OSU6162, a dopaminergic stabilizer with antipsychotic properties In: SCNP 43rd Annual and 2nd Mediterranean Meeting, Juan-les-Pins, France Nord J Psychiatry 56 2002 24
30. A. Lundin, E. Dietrichs, S. Haghighi, M.L. Göller, A. Heiberg, G. Loutfi Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease Clin Neuropharmacol 33 2010 260 264
31. C.A. Rodríguez, N.E. Azie, G. Adams, K. Donaldson, S.F. Francom, B.A. Staton, P.A. Bombardt Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers J Clin Pharmacol 44 2004 276 283
32. F. Benaliouad, S. Kapur, S. Natesan, P.P. Rompre Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion Eur Neuropsychopharmacol 19 2009 416 430
33. J.A. Simms, P. Steensland, B. Medina, K.E. Abernathy, L.J. Chandler, R. Wise, S.E. Bartlett Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats Alcohol Clin Exp Res 32 2008 1816 1823
34. R.A. Wise Voluntary ethanol intake in rats following exposure to ethanol on various schedules Psychopharmacology (Berl) 29 1973 203 210
35. S. Carnicella, R. Amamoto, D. Ron Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor Alcohol 43 2009 35 43
36. J. Li, W. Bian, V. Dave, J.H. Ye Blockade of GABA(A) receptors in the paraventricular nucleus of the hypothalamus attenuates voluntary ethanol intake and activates the hypothalamic-pituitary-adrenocortical axis Addict Biol 16 2011 600 614
37. B. Loi, C. Lobina, P. Maccioni, N. Fantini, M.A. Carai, G.L. Gessa, G. Colombo Increase in alcohol intake, reduced flexibility of alcohol drinking, and evidence of signs of alcohol intoxication in Sardinian alcohol-preferring rats exposed to intermittent access to 20% alcohol Alcohol Clin Exp Res 34 2010 2147 2154
38. S.A. McKee, E.L. Harrison, S.S. O'Malley, S. Krishnan-Sarin, J. Shi, J.M. Tetrault Varenicline reduces alcohol self-administration in heavy-drinking smokers Biol Psychiatry 66 2009 185 190
39. P. Steensland, J.A. Simms, J. Holgate, J.K. Richards, S.E. Bartlett Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking Proc Natl Acad Sci U S A 104 2007 12518 12523
40. D.J. Macey, G. Schulteis, S.C. Heinrichs, G.F. Koob Time-dependent quantifiable withdrawal from ethanol in the rat: Effect of method of dependence induction Alcohol 13 1996 163 170
41. I.T. Uzbay, S.E. Usanmaz, E.E. Tapanyigit, S. Aynacioglu, E.S. Akarsu Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: Association with behavioral signs Drug Alcohol Depend 53 1998 39 47
42. A. Imperato, G. Di Chiara Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis J Neurosci 5 1985 297 306
43. Y. Tizabi, R.L. Copeland Jr, V.A. Louis, R.E. Taylor Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens Alcohol Clin Exp Res 26 2002 394 399
44. A. Hadj Tahar, A. Ekesbo, L. Grégoire, E. Bangassoro, K.A. Svensson, J. Tedroff, P.J. Bédard Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys Eur J Pharmacol 412 2001 247 254
45. R.A. Lahti, C.A. Tamminga, A. Carlsson Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D(2) receptor function in vitro J Neural Transm 114 2007 1143 1146
46. K. Sahlholm, P. Arhem, K. Fuxe, D. Marcellino The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor Mol Psychiatry 2012
47. G. Di Chiara, A. Imperato Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats Proc Natl Acad Sci U S A 85 1988 5274 5278
48. E. Tupala, J. Tiihonen Dopamine and alcoholism: Neurobiological basis of ethanol abuse Prog Neuropsychopharmacol Biol Psychiatry 28 2004 1221 1247
49. E.K. Syvalahti, J. Hietala, M. Roytta, J. Gronroos Decrease in the number of rat brain dopamine and muscarinic receptors after chronic alcohol intake Pharmacol Toxicol 62 1988 210 212
50. S. Barak, S. Carnicella, Q.V. Yowell, D. Ron Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking J Neurosci 31 2011 9885 9894
51. M. Diana, M. Pistis, A. Muntoni, G. Gessa Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence Neuroscience 71 1996 411 415
52. Z.L. Rossetti, F. Melis, S. Carboni, M. Diana, G.L. Gessa Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine Alcohol Clin Exp Res 16 1992 529 532
53. I.W. Beczkowska, W.D. Bowen, R.J. Bodnar Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats Brain Res 589 1992 291 301
54. R.L. Corwin, F.H. Wojnicki Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions Behav Pharmacol 20 2009 537 548
55. M.F. Stromberg, M.R. Rukstalis, S.A. Mackler, J.R. Volpicelli, C.P. O'Brien A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats Pharmacol Biochem Behav 72 2002 483 490
56. A. Hajnal, G.P. Smith, R. Norgren Oral sucrose stimulation increases accumbens dopamine in the rat Am J Physiol Regul Integr Comp Physiol 286 2004 R31 R37
57. R. Spangler, K.M. Wittkowski, N.L. Goddard, N.M. Avena, B.G. Hoebel, S.F. Leibowitz Opiate-like effects of sugar on gene expression in reward areas of the rat brain Brain Res Mol Brain Res 124 2004 134 142
58. F.M. Ferraro 3rd, K.G. Hill, H.J. Kaczmarek, D.L. Coonfield, S.W. Kiefer Naltrexone modifies the palatability of basic tastes and alcohol in outbred male rats Alcohol 27 2002 107 114